Comparative Pharmacology
Head-to-head clinical analysis: DUETACT versus PIOGLITAZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUETACT versus PIOGLITAZONE.
DUETACT vs PIOGLITAZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUETACT is a fixed-dose combination of pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ), and glimepiride, a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Selective agonist at peroxisome proliferator-activated receptor-gamma (PPAR-γ), modulating transcription of genes involved in glucose and lipid metabolism, increasing insulin sensitivity in adipose tissue, muscle, and liver.
Initial dose: 30 mg pioglitazone/2 mg glimepiride orally once daily; titrate based on glycemic control; maximum dose: 45 mg pioglitazone/8 mg glimepiride daily.
15-30 mg orally once daily; maximum dose 45 mg/day.
None Documented
None Documented
Clinical Note
moderatePioglitazone + Gatifloxacin
"Pioglitazone may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderatePioglitazone + Rosoxacin
"Pioglitazone may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderatePioglitazone + Levofloxacin
"Pioglitazone may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderatePioglitazone + Trovafloxacin
"Pioglitazone may increase the hypoglycemic activities of Trovafloxacin."
Pioglitazone: terminal half-life 3-7 hours (parent drug), 16-24 hours (active metabolites); clinical context: once-daily dosing sufficient due to active metabolites. Glimepiride: terminal half-life 5-8 hours; clinical context: supports once- or twice-daily dosing in type 2 diabetes.
Terminal elimination half-life is 3-7 hours in healthy adults, but extends to 16-24 hours in patients with hepatic impairment due to reduced clearance. Steady-state is achieved after 4-6 days of dosing.
Pioglitazone is primarily excreted in feces (55%) as metabolites, with renal excretion accounting for 30% (primarily as metabolites and <5% unchanged). Glimepiride is excreted in urine (60% as metabolites, ~25% unchanged) and feces (40% as metabolites).
Primarily hepatic metabolism via CYP2C8 and CYP3A4; approximately 15-30% excreted in urine as metabolites, with the remainder in feces (~70%) via biliary elimination. Renal excretion of unchanged drug is negligible (<1%).
Category C
Category A/B
Thiazolidinedione/Sulfonylurea Combination
Thiazolidinedione